These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26973142)

  • 1. The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis.
    Johnsen E; Fathian F; Kroken RA; Steen VM; Jørgensen HA; Gjestad R; Løberg EM
    BMC Psychiatry; 2016 Mar; 16():60. PubMed ID: 26973142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis.
    Fathian F; Løberg EM; Gjestad R; Steen VM; Kroken RA; Jørgensen HA; Johnsen E
    Acta Neuropsychiatr; 2019 Feb; 31(1):36-45. PubMed ID: 30394240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder.
    Dickerson F; Stallings C; Origoni A; Vaughan C; Khushalani S; Yolken R
    J Affect Disord; 2013 Sep; 150(2):456-9. PubMed ID: 23684514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia.
    Dickerson F; Stallings C; Origoni A; Boronow J; Yolken R
    Schizophr Res; 2007 Jul; 93(1-3):261-5. PubMed ID: 17490859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia.
    Dickerson F; Stallings C; Origoni A; Vaughan C; Khushalani S; Yolken R
    Schizophr Res; 2012 Jan; 134(1):83-8. PubMed ID: 22048011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls.
    Jacomb I; Stanton C; Vasudevan R; Powell H; O'Donnell M; Lenroot R; Bruggemann J; Balzan R; Galletly C; Liu D; Weickert CS; Weickert TW
    Front Immunol; 2018; 9():2230. PubMed ID: 30364161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients.
    Heitz U; Papmeyer M; Studerus E; Egloff L; Ittig S; Andreou C; Vogel T; Borgwardt S; Graf M; Eckert A; Riecher-Rössler A
    World J Biol Psychiatry; 2019 Sep; 20(7):545-554. PubMed ID: 29938562
    [No Abstract]   [Full Text] [Related]  

  • 9. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users.
    Chen CK; Lin SK; Chen YC; Huang MC; Chen TT; Ree SC; Wang LJ
    Drug Alcohol Depend; 2015 Mar; 148():158-64. PubMed ID: 25601645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study.
    Martínez-Cengotitabengoa M; Micó JA; Arango C; Castro-Fornieles J; Graell M; Payá B; Leza JC; Zorrilla I; Parellada M; López MP; Baeza I; Moreno C; Rapado-Castro M; González-Pinto A
    Schizophr Res; 2014 Jun; 156(1):23-9. PubMed ID: 24768133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms.
    Stojanovic A; Martorell L; Montalvo I; Ortega L; Monseny R; Vilella E; Labad J
    Psychoneuroendocrinology; 2014 Mar; 41():23-32. PubMed ID: 24495605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A longitudinal study of cognitive functioning in schizophrenia: clinical and biological predictors.
    Dickerson F; Schroeder J; Stallings C; Origoni A; Katsafanas E; Schwienfurth LA; Savage CL; Khushalani S; Yolken R
    Schizophr Res; 2014 Jul; 156(2-3):248-53. PubMed ID: 24827555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-reported cognitive distortions in the psychosis continuum: A Polish 18-item version of the Davos Assessment of Cognitive Biases Scale (DACOBS-18).
    Gawęda Ł; Prochwicz K; Krężołek M; Kłosowska J; Staszkiewicz M; Moritz S
    Schizophr Res; 2018 Feb; 192():317-326. PubMed ID: 28601498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive changes in patients with acute phase psychosis--effects of illicit drug use.
    Helle S; Gjestad R; Johnsen E; Kroken RA; Jørgensen HA; Løberg EM
    Psychiatry Res; 2014 Dec; 220(3):818-24. PubMed ID: 25240944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration?
    Becker HE; Nieman DH; Wiltink S; Dingemans PM; van de Fliert JR; Velthorst E; de Haan L; van Amelsvoort TA; Linszen DH
    Psychol Med; 2010 Oct; 40(10):1599-606. PubMed ID: 20132582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum high sensitivity C-reactive protein and cognitive function in elderly women.
    Komulainen P; Lakka TA; Kivipelto M; Hassinen M; Penttilä IM; Helkala EL; Gylling H; Nissinen A; Rauramaa R
    Age Ageing; 2007 Jul; 36(4):443-8. PubMed ID: 17537742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups.
    Joseph J; Depp C; Martin AS; Daly RE; Glorioso DK; Palmer BW; Jeste DV
    Schizophr Res; 2015 Oct; 168(1-2):456-60. PubMed ID: 26341579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight dimensions and cognitive function in psychosis: a longitudinal study.
    Cuesta MJ; Peralta V; Zarzuela A; Zandio M
    BMC Psychiatry; 2006 May; 6():26. PubMed ID: 16737523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of interrelationships between cognitive performance, symptomatic manifestation and social functioning in the acute and clinical stability phase of schizophrenia: insights from a network analysis.
    Misiak B; Piotrowski P; Samochowiec J
    BMC Psychiatry; 2023 Oct; 23(1):774. PubMed ID: 37875888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between salivary C-reactive protein and cognitive function in children aged 11-14years: Does psychopathology have a moderating effect?
    Cullen AE; Tappin BM; Zunszain PA; Dickson H; Roberts RE; Nikkheslat N; Khondoker M; Pariante CM; Fisher HL; Laurens KR
    Brain Behav Immun; 2017 Nov; 66():221-229. PubMed ID: 28694011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.